关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
2 k* Z7 ^# k" {) U
. r' M# U9 p( X- V3 I作者：来自澳大利亚
0 i( f6 A" x# E$ b! I, a1 F来源：Haematologica. 2011.8.9.
Dear Group,

Some of you are on Dasatinib (Sprycel) and we wish to give news on all CML
# S8 @3 {- p, G- [  Z: \: P0 Rtherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
  A% Q) ^7 L3 V  `remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
8 K# Q+ _. G, |+ v% Y' {1 t
+ X* [7 y3 P' g6 wThe remarkable news about Sprycel cessation is that all 3 patients had failed
% K6 |4 n7 `4 l+ eGleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
" |" E$ I2 q5 s/ b7 i2 u1 o4 fwho have done well on Gleevec.
) j. G, d9 m+ q/ \9 i
3 Q# X, M# v- r! J$ y/ p! X$ H) r/ RHopefully, the doctors will report on a larger study and long-term to see if the
1 g3 n! _/ l" y9 f# Bresponse off Sprycel is sustained.
$ c- J4 u6 [. N1 ^! |4 i' l3 A
Best Wishes,
Anjana
) U$ ^. r5 u, q' t/ k4 b6 k% Q
+ U1 M- q+ X5 z) m7 r4 F
, I9 {! I! v; `; b0 ^6 S1 c
1 p3 H7 ], f) `7 |Haematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
- J. V' A+ P- a7 i5 {. K" LSource
5 F( Z6 y5 V1 x# Y3 m- ZAdelaide, Australia;

/ m* L' O2 F" t4 iAbstract
7 A) Z' I6 |, M# ?Patients with chronic myeloid leukemia, treated with imatinib, who have a
+ p' f3 i- V( ^: U8 k; Mdurable complete molecular response might remain in CMR after stopping
3 S" R- f4 P) G4 N4 Rtreatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
2 z; g7 c7 k; E+ C: s  wdescribe three patients with stable complete molecular response on dasatinib
) z' g9 Z5 [  Y! v0 W3 H# Utreatment following imatinib failure. Two of the three patients remain in
9 V; ?) P8 ^7 ]& ^7 z9 l% `complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
& q1 `3 U, M3 `: d7 u* T& qimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
0 ^+ t* ?$ Q7 O' icharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
' H" Y& x) c* ~7 N! A& ^( {3 S6 L  ddisease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
0 d8 t8 n5 v, C" k    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
8 [! E  W3 X6 d7 k  D
作者：来自法国STIM试验
2 ^4 O  r1 t1 U, y) t8 K, p来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事